FDA Brief

Warning letters Drugs

FDA warning letter to

VarunKart Group LLC dba Organic Wellnesses

High riskIssued Nov 17, 2025Posted Nov 25, 2025Center for Drug Evaluation and Research (CDER)

VarunKart Group sells unapproved Ayurvedic and homeopathic drugs with serious disease claims.

What happened

In September 2025, FDA reviewed the Organic Wellnesses website and found nine products offered for sale with labeling claims to cure, mitigate, treat, or prevent serious conditions such as measles, tuberculosis, cancer, diabetes, and hepatitis, plus two eye drops. FDA concluded the products are drugs and unapproved new drugs because no FDA-approved applications are in effect.

What FDA found

  1. The products are unapproved new drugs sold without FDA-approved applications.

    FD&C Act sections 301(d) and 505(a), 21 U.S.C. 331(d) and 355(a)
  2. Website labeling shows the products are intended to cure, mitigate, treat, or prevent disease, making them drugs.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1); 21 CFR 201.128
  3. The products are new drugs because they are not generally recognized as safe and effective for their labeled uses.

    FD&C Act section 201(p), 21 U.S.C. 321(p)
  4. Homeopathic products are not exempt from drug approval requirements.

    FD&C Act section 201(g)(1), 21 U.S.C. 321(g)(1)

What FDA wants

Within 15 working days of receipt, notify FDA in writing of the specific steps taken to correct the violations, explain steps to prevent recurrence, and include related documentation. If corrective action cannot be completed within 15 working days, state the reason for delay and the time within which it will be completed, sending the response to FDAAdvisory@fda.hhs.gov with firm name and identifier 716154.

Who should pay attention

  • online retailers of imported Ayurvedic or homeopathic products
  • marketplaces and brands that publish disease-treatment claims
  • consumers using eye drops or products claiming to treat serious diseases

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk